Repros Therapeutics — Investor Presentation (January 2015)
63 slides from Repros Therapeutics's investor presentation, Jan 12, 2015
Slide 1: Androxal: A Mechanistically Consistent Approach to Secondary Hypogonadism
Androxal ® January, 2015 A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism 1
Slide 2: Repros Disclaimer
Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertai
Slide 3: Androxal Indication Statement
Androxal Indication Statement “4.1 INDICATION FOR USE* Androxal is indicated for the oral treatment of hypogonadotrophic hypogonadism (secondary hypogonadism) with preservation of testicular function (sperm concentration >15 million/mL and endogenous testosterone production) in men with BMI over 25.
Slide 4: Androxal Regulatory Status
Androxal Regulatory Status • Draft Androxal NDA dossier completed • NDA user fee, $2.3 million, sent to FDA • Anticipate NDA submission following conversion of dossier to Electronic submission by contractor during Q1, 2015 • Anticipate PDUFA date of Q1 2016 for decision on approval • Repros is reque
Slide 5: Androxal Regulatory Status (cont'd)
Androxal Regulatory Status • Key NDA components (cont’d) – Integrated summary of safety • Exceeds ICH requirements for exposure • > 1500 men exposed (any dose, any duration) • > 900 men for 6 months • > 200 men for 12 months • > 700 patient years of exposure – CMC components • DMF submitted to FDA b
Slide 6: Androxal Intellectual Property
Androxal Intellectual Property • FAMILY 1 – TRANS - CLOMIPHENE FOR TREATING TESTOSTERONE DEFICIENCY (BASE PATENT FAMILY) – US10/483,458, Granted 7,759,360, March 19, 2023 in US, July 9, 2022 elsewhere • FAMILY 2 – TRANS - CLOMIPHENE DOSING REGIMES – Priority – US 60/664,290 Filed March 22, 2005 • FA
Slide 7: Key Literature Observation Regarding Secondary Hypogonadism and Repros Clinical Findings
Key Literature Observation Regarding Secondary Hypogonadism and Repros Clinical Findings from Androxal Studies 7
Slide 8: Categorising Gonadal Status by Testosterone and LH in EMAS
Categorising Gonadal Status by Testosterone (T) and LH in the European Male Ageing Study (EMAS) : A General Population Observational Cohort Study Thresholds for abnormal: <Total T 10.5 nmol /L (300 ng/ dL ) and >LH 9.4 U/L (Tajar et al J Clin Endocrinol Metab 2010 95:1810) 0 20 40 60 80 LH (U/L) 0 1
Slide 9: Secondary Hypogonadism at Baseline
Secondary Hypogonadism at Baseline Age (years) BMI ≥ 25 - <30 kg/m2 BMI ≥ 30 kg/m2 Smoking (current) Alcohol (frequent) Morbidity ( ≥ 1) 0 5 10 15 *** *** * Poor morning erection Sexual thoughts Erectile dysfunction Low vigorous activity Unable to bend Slow walking speed 0 2 4 6 * * Adjusted Relativ
Slide 10: Primary Hypogonadism at Baseline
Primary Hypogonadism at Baseline Poor morning erection Sexual thoughts Erectile dysfunction Low vigorous activity Unable to bend Slow walking speed 0 2 4 6 Age (years) BMI ≥ 25 - <30 kg/m2 BMI ≥ 30 kg/m2 Smoking (current) Alcohol (frequent) Morbidity ( ≥ 1) 0 5 10 15 *** * ** *p <0.05 **p< 0.01 ***p
Slide 11: Greater Effects of BMI on Reproductive Hormone Levels in EMAS
Wu et al. JCEM 2008 Greater Effects of BMI ( cf to Age) on Reproductive Hormone Levels in EMAS - Indicating Secondary Hypogonadism in Obesity (n = 3210) 11
Slide 12: Obesity in America
The . Economist Containing obesity Login The last course What will it take to make the world less round? Rat of obesty Rasa | I Obesity in America was of adults with BMI” 230, 2011 Obesity prevalence as % of total population* United Arab United == —= Brazil Emirates State aes — South Africa Britain
Slide 13: Hormone Changes Related to Weight Loss/Gain
Hormone Changes (Rise/Fall) are Related to % Weight Loss/Gain (Data adjusted for age , centre, changes in smoking status, alcohol consumption co - morbidities & physical activity) n = 2395, *p<0.05, **p<0.01 % Weight loss Weight gain % 0 * ** * * * * * * ** ** ** ** * Camacho et al. European Journal
Slide 14: Weight in Hypogonadal Men Treated with Testosterone Undecanoate
85 90 95 100 105 110 115 120 125 130 Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Grade I Grade II Grade III Weight (kg) in 362 Hypogonadal Men with Different Grades of Obesity Treated with Injections of Testosterone Undecanoate for up to 6 Years * * * * 185 159 141 126 84 177 169 Gr. I n = *
Slide 15: Age & BMI of Subjects in Repros Androxal Studies
Age & BMI of Subjects in Repros Androxal Studies Study IND # of Subjects Mean Age Mean BMI ZN - 018 65,396 52 51.2 31.95 ZA - 003 65,396 194 52.6 32.4 ZA - 202 104,921 116 57.3 33.5 ZA - 203 65,396 108 50.7 32.0 ZA - 204 65,396 60 53.1 31.8 ZA - 300 65,396 499 48.6 33.0 ZA - 301 65,396 151 46.5 31.8
Slide 16: Two Separate Tracks of Hypogonadism
Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Two Separate Tracks of Hypogonadism 1. Secondary hypogonadism associated with ob
Slide 17: Endocrine Mechanism Controlling Testicular Function
A B Endocrine Mechanism Controlling Testicular Function (A) and the Suppressive Effects of Exogenous Testosterone on Testicular Functions (B) (Adapted from Nieschlag 2010) Exogenous Testosterone
Slide 18: Androxal Efficacy
Androxal ® Efficacy A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism 18
Slide 19: Androxal Averages: % of Men Studied in Normal Range
Androxal Averages > 75 % of Men Studied in Normal Range • 10 studies conducted with durations up to 1 year • Table determined as LOCF for morning T Study Subjects Receiving Androxal Study Duration % Morning T in Normal Range (LOCF) ZN - 018 22 2 Wks. 77.3 ZA - 003 97 3 Mo. 63.9 ZA - 203 57 3 Mo. 68.
Slide 20: FDA Concerns over Morning T to Predict Tmax and Tavg
FDA Concerns over Morning T to Predict Tmax and Tavg Repros analysis shows strong correlation with morning T for men on Androxal 20
Slide 21: ZA-304/305 Study Design
ZA - 304/305 • Comparison of Androxal, Androgel 1.62% and Placebo • Double dummy, double blind parallel design with titration provisions within an arm – 40 per arm – Men < 60 years old and BMI > 25 – Confirmed morning T < 300 ng/dL – Average sperm counts at baseline > 15 million per mL • Primary end
Slide 22: Studies Comparing Androxal to Topical Gel: Testosterone Levels
Studies Comparing Androxal to Topical Gel Impact on Testosterone Levels (LOCF) 0 10 20 30 40 50 60 70 80 90 100 ZA-003 ZA-203 ZA-304 ZA-305 % of Men in Normal Range Comparison of Morning T Androxal Topical Gel 0 10 20 30 40 50 60 70 80 90 100 ZA-304 ZA-305 % of Men in Normal Range Comparison of 24 H
Slide 23: ZA-304 Secondary Endpoint: Changes in LH & FSH
ZA - 304, 305 Secondary Endpoint Comparison of Changes in LH & FSH 0 1 2 3 4 5 6 7 8 9 10 LH 304 Baseline LH 304 EOS LH 305 Baseline LH 305 EOS FSH 304 Baseline FSH 304 EOS FSH 305 Baseline FSH 305 EOS LH & FSH (mIU/mL) Median LH and FSH Androxal Androgel Placebo Androxal vs Androgel p<0.0001 For al
Slide 24: Comparison of Impact on Sperm
ZA - 304 & ZA - 305 (16 Week Studies) Comparison of Impact on Sperm 0 20 40 60 80 100 120 Baseline Sperm EOS Sperm Mean Sperm Concentration X 10 6 Change in Sperm Concentration 304 Androxal 305 Androxal 304 Androgel 305 Androgel 304 Pbo 305 Pbo 0 10 20 30 40 50 60 70 80 90 100 ZA-304 ZA-305 % of Sub
Slide 25: First Co-Primary Efficacy Endpoint: Sperm Concentration
ZA - 304 & 305 First Co - Primary Efficacy Endpoint % Change from Baseline Sperm Concentration Androxal vs Androgel -80 -70 -60 -50 -40 -30 -20 -10 0 10 ZA-304 ZA-305 % Change from Baseline Androxal Androgel p - value <0.0001 p - value =0.0004 25
Slide 26: Second Co-Primary Efficacy Endpoint: Normal T and Sperm
ZA - 304 & 305 Second Co - Primary Efficacy Endpoint % Normal T and Sperm Concentration Androxal vs Androgel 0 10 20 30 40 50 60 70 ZA-304 ZA-305 % Normal Androxal Androgel p - value <0.0001 p - value =0.0047 26
Slide 27: Change in Testicular Volume by Orchidometry
Change in Testicular Volume by Orchidometry 16.5 17 17.5 18 18.5 19 19.5 20 20.5 21 21.5 22 304 BL Test. Vol. 304 EOS Test. Vol> 305 BL Test. Vol. 305 EOS Test. Vol> cm 3 Androxal Androgel Pbo 304 p - value =0.014 305 p - value =0.026 Comparing Androxal to Androgel 27
Slide 28: Baseline T to One Week Post Treatment
Impact of 16 Weeks of Treatment Comparing Baseline T to One Week Post Treatment 0 50 100 150 200 250 300 350 400 Baseline T Off Drug T Morning T (ng/ dL ) 304 Androxal 305 Androxal 304 Androgel 305 Androgel 304 Pbo 305 Pbo One Week After Treatment Androxal vs Androgel p <0.0001 Androgel BL vs Androg
Slide 29: Studies ZA-301 and ZA-302 Complete the Efficacy Package
Studies ZA - 301 and ZA - 302 Complete the Efficacy Package 0 10 20 30 40 50 60 70 80 90 100 ZA-301 ZA-302 % of Subjects in Normal Range for 24 Hr Avg. T 95% CI ( 69.5 , 85.1) 95% CI ( 73.9 , 87.0) 0 10 20 30 40 50 60 70 80 90 100 ZA-301 ZA-302 % of Subjects with Normal T and Sperm Conc.> 10 X 10 6
Slide 30: Androxal Safety
Androxal ® Safety A Generally Well Tolerated Approach to the Treatment of Secondary Hypogonadism 30
Slide 31: Treatment Emergent Adverse Events: Studies 301 and 302
TREATMENT EMERGENT ADVERSE EVENTS Studies 301 and 302 Study 301 Study 302 Preferred Term 12.5 mg (%) 25 mg (%) PBO (%) 12.5 mg (%) 25 mg (%) PBO (%) N 91 21 37 112 22 47 Any Event 28 24 24 35 36 34 Diarrhea 2 0 3 2 0 0 Dyspepsia 2 0 0 1 0 2 Nausea 0 0 5 4 5 6 Hot flush 1 0 0 2 0 0 Influenza 2 0 3 0
Slide 32: Treatment Emergent Adverse Events: ZA-304 & 305
ZA - 304 ZA - 305 Androxal Pooled Androgel Placebo Androxal Pooled Androgel Placebo N=41 N=43 N=45 N=44 N=42 N=41 (%) (%) (%) (%) (%) (%) Any event 48.8 41.9 42.2 45.5 47.6 46.3 Preferred Term Cataract 0 6.7 0 0 0 0 Abnormal Weight Gain 0 0 0 2.3 4.8 2.4 Arthralgia 2.4 4.7 0 0 0 2.4 Cough 0 0 0 0 4.
Slide 33: Treatment Emergent Adverse Events: Studies 300 and 303
TREATMENT EMERGENT ADVERSE EVENTS Studies 300 and 303 Study 300 (>2% in either dose) Study 303 (>2% in either Androxal group ) Preferred Term 12.5 mg (%) 25 mg (%) 12.5 mg (%) 25 mg (%) PBO (%) N 207 283 122 92 104 Any Event 59.9 58.7 62.3 62.6 51.0 CONSTIPATION 1.9 2.5 0 0 0 DIARRHEA 1,9 1.0 2.5 1.
Slide 34: Treatment Emergent Adverse Events (continued)
TREATMENT EMERGENT ADVERSE EVENTS Studies 300 and 303 (continued) Study 300 (>2% in either dose) Study 303 (>2% in either Androxal group ) Preferred Term 12.5 mg (%) 25 mg (%) 12.5 mg (%) 25 mg (%) PBO (%) N 207 283 122 92 104 Any Event 59.9 58.7 62.3 62.6 51.0 ARTHRALGIA 2.0 1.8 5.7 3.3 2.0 BACK PA
Slide 35: Financial Summary
Financial Summary • Cash and equivalents (unaudited year end 2014) $46.6 M • Estimated Burn in 2015 : $22.0 M • Cash runway: Through 2016 – Anticipate Androxal approved • Current shares outstanding: 24.3 M shares – Warrants Outstanding – Series A – 39,595 (purchased in unit deal @ $2.45); Series B –
Slide 36: Conclusions
CONCLUSIONS • Androxal is well tolerated • Findings are consistent with known pharmacology • Thrombotic events (with or without Hct increase) are an established risk (similar to topical testosterone) • No unexpected safety issues 36
Slide 37: Clinical Implications
Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Clinical Implications • Secondary hypogonadism is closely associated with obesit
Slide 38: Summary of Provider and Payer Perspectives Regarding Androxal
Summary of Provider and Payer Perspectives Regarding Androxal October 31, 2014
Slide 39: Secondary Hypogonadism TRT Usage
Secondary Hypogonadism Testosterone Replacement Therapy (TRT) Usage On average, three quarters of secondary hypogonadism patients are on TRT regardless of physician specialty, with Androgel as the most often mentioned choice. Total Physician Respondents (n=30) Uro (n=10), Endo (n=10), PCP (n=10) Fre
Slide 40: Current Satisfaction with Available Treatments
Secondary Hypogonadism Current Satisfaction with Available Treatments Physicians are less satisfied with current treatments than the think their patients are. Physician Satisfaction Perceived Patient Satisfaction Count of Physicians Total Physician Respondents (n=30) Uro (n=10), Endo (n=10), PCP (n=
Slide 41: Secondary Hypogonadism Unmet Needs
Secondary Hypogonadism Unmet Needs The top unmet needs were a better route of administration and testicular function/infertility. Comments About Unmet Needs ▪ A third of providers voiced minor - moderate concern over CV risks. ▪ Physicians do not view transference as a major problem. ▪ Although TRT
Slide 42: Androxal Review: Expected Physician Usage
Androxal Review Expected Physician Usage All providers in the study would consider using Androxal as a first line treatment and would place nearly 60 of their next 100 secondary hypogonadal patients on Androxal. First Line Treatment Mentions Total Physician Respondents (n=30) Uro (n=10), Endo (n=10)
Slide 43: Payer Pricing Expectations
Unaided, a majority believed that Androxal would be priced similar to branded TRTs and, at that price, would be covered. Androxal Review Payer Pricing Expectations Responses Payer Expectations of Androxal Price 43
Slide 44: Key Commercial Conclusions
Conclusions Key Commercial Conclusions ▪ Payers and providers recognize room for improvement with current treatment options and are becoming more aware of the downsides of TRTs. ▪ Additional education will be important to inform physicians and payers as to the issues associated with testosterone rep
Slide 45: Proellex
Proellex ® 45
Slide 46: Proellex Overview
Proellex Overview • Selective progesterone receptor modulator (SPRM) • Potential indications: uterine fibroids, endometriosis, breast cancer • Potential significant advantages over existing GnRHa therapies – No loss of bone mineral density in clinical trials – No chronic drug treatments available •
Slide 47: How Proellex Works
O O OMe N OAc CH 3 H 3 C How Proellex Works • Blocks hypothalamus / pituitary axis • Shuts down hormonal secretions • Long - term side effects including bone loss • Selectively blocks progesterone activity • Allows tonic hormone secretions – Alleviates negative side effects of GnRHa • Potential for
Slide 48: An Effective Dose of Proellex Stops Menstruation
An Effective Dose of Proellex Stops Menstruation in Majority of Women 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with Induced Amenorrhea Proellex induced amenorrhea Mimics early follicular phase Without progesterone Key symptoms of both fibroids and endometrios
Slide 49: Uterine Fibroids
Uterine Fibroids • Benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus • Most common tumor of the female reproductive tract – Heavy bleeding / anemia – Abdominal pressure / pain / urinary frequency • Affect 20 - 77% of women age 35 – 55 • 600,000 hysterectomies conducted annual
Slide 50: Key Symptom Driving Women to Seek Therapy for Uterine Fibroids
Key Symptom Driving Women to Seek Therapy for Uterine Fibroids Excessive Menstrual Bleeding Early Development Results Proellex Stops Menses 0 2 4 6 8 10 12 14 Days of Bleeding Over 4 Mo. 12.5 25 50 Lupron Placebo Days of Vaginal Bleeding Over 4 Months Spotting Light Moderate Heavy European Pilot Stu
Slide 51: Proellex Produces Significant Clinical Benefit in Uterine Fibroids
Proellex Produces Significant Clinical Benefit Resulting in Substantially Asymptomatic Uterine Fibroids Early Development Results 0 10 20 30 40 50 60 70 80 90 UFSQOL SCORE Symptom Severity Concern Placebo 12.5 mg Proellex 25 mg Proellex Normal UFSQOL Uterine Fibroid Symptom Survey p vs placebo < 0.0
Slide 52: Endometriosis
• Definition: the presence of epithelial and stromal endometrial cells outside of the uterine cavity • Complaints of infertility or pregnancy loss • Pelvic pain/back pain • Dyspareunia (pain during sex) • Dysmenorrhea (menstrual cycle cramps) Endometriosis • 5% of women of reproductive age • Estimat
Slide 53: High Dose Proellex Endometriosis Pain Results
Initial Study of High Dose Proellex Yielded Statistical Significance for Key Endometriosis Pain Elements 0 10 20 30 40 50 60 70 80 90 100 % of Baseline Pain Impact on Painful Menses Placebo Proellex p<0.0001 N = 18 Placebo N = 40 Placebo 0 10 20 30 40 50 60 70 80 90 100 % of Baseline Pain Impact on
Slide 54: Proellex Eliminates Pain and Need for Analgesics in Endometriosis
Proellex Eliminates the Pain and Need for Analgesics to Control the Pain of Endometriosis 55.5 22.2 13.6 0 10 20 30 40 50 60 70 80 90 100 Placebo 25mg Proellex 50mg Proellex % of Subjects Requiring Narcotics By End of Study Baseline End of Study P<0.01 28 Hallmark pain symptom for endometriosis is p
Slide 55: Proellex Does Not Suppress LH and Estrogen to Menopausal Levels
Proellex Does Not Suppress LH and Estrogen to Menopausal Levels (ZPE - 002) Compared to Central Acting Treatment 0 20 40 60 80 100 120 140 Serum Estradiol (pg/ml) Baseline Month 3 Month 6 Lupron 12.5 mg Proellex 25 mg Proellex 50 mg Proellex 0 2 4 6 8 10 Baseline Month 3 Month 6 Median LH Levels Lup
Slide 56: Lupron Increases Bone Turnover, Proellex Does Not
Lupron Increases Bone Turnover Proellex Does Not (ZN - 001) Mean Proellex 12.5 mg Proellex 25 mg Proellex 50 mg Lucron 3.75 mg Placebo (Nl: normal range) Number of patients 6 6 6 5 6 Bone resorption marker CTX (Nl: 0.03 - 0.57 ng/l) Baseline 0.3 0.4 0.3 0.2 0.4 3 Months TXT (Visit 5) 0.4 0.4 0.4 0.6
Slide 57: Vaginal Delivery of Proellex
Vaginal Delivery of Proellex • Avoid 1 st - pass liver effects • Achieve high local concentrations • Formulation Developed (using standard excipients) Completed Phase 2 study in uterine fibroids • FDA recommends Phase 2b before proceeding to Phase 3 • Phase 2b study initiated 57
Slide 58: Systemic Exposure to Oral Proellex Varies by Dose
Systemic Exposure to Oral Proellex Varies in a Dose Dependent Manner Significant reduction in exposure via vaginal delivery 0 200 400 600 800 1000 1200 1400 1600 1800 12 mg vaginal 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg Concentration ( ng /ml) Combined Cmax for Telapristone and Primary Metabolite Liv
Slide 59: Vaginal Proellex Induces Amenorrhea
Vaginal 12 mg Proellex Induces Amenorrhea 0 20 40 60 80 100 120 Baseline Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Median Pictorial Blood Loss Score N=11 p=0.0025 59
Slide 60: Proellex Open Label Update (12 mg dose)
ZPV - 200 Ext. Proellex Open Label Update (12mg dose) 0 10 20 30 40 50 60 70 80 90 100 Baseline End of 1st Cycle End of 2nd Cycle % of Initial Volume 12mg in initial treatment (n=15 fibroids) 3 or 6mg in initial treatment (n=14 fibroids) Paired Comparison for Subjects Dosed at 12 Throughout Study •
Slide 61: Current Clinical Activity: Uterine Fibroids
Current Clinical Activity Uterine Fibroids • Phase 2b Programs – Initiated Low Dose Oral Phase 2b study – Initiated Vaginal Administration Phase 2b study • Identical designs – Placebo, 12 mg and 6 mg doses – 3 arm parallel design (15 subjects per arm) • All subjects with confirmed fibroids and menst
Slide 62: Current Clinical Activity: Endometriosis
Current Clinical Activity Endometriosis • Low Dose Oral Program – Ongoing 60 subjects Phase 2 study – 20 each @ placebo, 6mg and 12 mg – 4 month dosing – Primary endpoint: change in BBSS score – Secondary endpoint: reduction in analgesic use • Stalled enrollment – Anticipate enrollment completed dur
Slide 63: Overall Conclusions and Plans Going Forward
Overall Conclusions and Plans Going Forward • Proellex is an effective medical treatment for – Uterine fibroids • Rapid and maintained reduction in bleeding • Significant restoration of QOL • Rapid recovery of anemia • Reduction of fibroid bulk • Reduction of bulk associated symptoms – Endometriosis
Repros Therapeutics — Investor Presentation (January 2015) on 6ix